Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Angelo Belotti, MD, Rossella Ribolla, Valeria Cancelli, MD, Nicola Bianchetti, Claudia Crippa, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Cattaneo, MD, Vincenza Orlando, PharmD, Marco Chiarini, Luigi Grazioli, MD, Giuseppe Rossi

Blood (2018) 132 (Supplement 1): 2151.

https://doi.org/10.1182/blood-2018-99-113022

Published: 2018

Journal Articles

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Angelo Belotti, MD, Rossella Ribolla, MD, Claudia Crippa, MD, Chiara Cattaneo, MD, Enrico Morello, MD, Vincenza Orlando, PharmD, Nicola Bianchetti, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Francesca Schieppati, MD, Aldo M. Roccaro, Marco Chiarini, Mario Morone, MD, Giuseppe Rossi, MD

Blood (2017) 130 (Supplement 1): 3161.

https://doi.org/10.1182/blood.V130.Suppl_1.3161.3161

Published: 2017

Journal Articles

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Carlo Gambacorti-Passerini, MD, Sergey Orlov, Li Zhang, Fadi Braiteh, Huiqiang Huang, Taito Esaki, Keizo Horibe, Jin-Seok Ahn, Joseph T. Beck, William Jeffrey Edenfield, Yuankai Shi, Matthew Taylor, Kenji Tamura, Brian A. Van Tine, Shang-Ju Wu, MD, PhD, Jolanda Paolini, Sherry Li, Tae Min Kim

Blood (2017) 130 (Supplement 1): 4128.

https://doi.org/10.1182/blood.V130.Suppl_1.4128.4128

Published: 2017

Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD

Blood (2017) 130 (Supplement 1): 838.

https://doi.org/10.1182/blood.V130.Suppl_1.838.838

Published: 2017

Journal Articles

Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies

Hideki Tsujimura, MD, Kyoya Kumagai, MD, Takanori Teshima, MD PhD, Kiyohiko Hatake, MD PhD, Koji Izutsu, MD PhD, Kiyoshi Ando, MD PhD, Tomohiro Kinoshita, MD PhD, Takayuki Ishikawa, MD PhD, Koji Kato, MD PhD, Eisuke Ueda, Kiyohiko Nakai, Hiroshi Kuriki, Kensei Tobinai, MD, PhD

Blood (2016) 128 (22): 5389.

https://doi.org/10.1182/blood.V128.22.5389.5389

Published: 2016

Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity

Perrine Guillaume-Jugnot, MD, Zora Marjanovic, Myriam Labopin, MD, Louis Terriou, MD, Christophe Deligny, Bruno Lioure, MD, Thierry Martin, Veronique Leblond, MD PhD, Gregory Pugnet, Didier Blaise, Régis Peffault de Latour, MD, Ibrahim Yakoub-Agha, MD PhD, John A Snowden, MD FRCP, FRCPath, Dominique Farge, PhD MD

Blood (2015) 126 (23): 1985.

https://doi.org/10.1182/blood.V126.23.1985.1985

Published: 2015

Journal Articles

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD, Joseph Leach, MD, W. Christopher Ehmann, MD, Kiyoshi Ando, MD, PhD, Kiyohiko Hatake, MD, PhD, Kensei Tobinai, MD, PhD, Tatyana Feldman, MD, Steven Hua, Angela DG Volkert, Erik R. Vandendries, MD, PhD, Michinori Ogura, MD, PhD

Blood (2010) 116 (21): 430.

https://doi.org/10.1182/blood.V116.21.430.430

Published: 2010

Journal Articles

Clinical Significance of Small Intestinal Involvement Detected by Double-Balloon Enteroscopy In Patients with Non-Hodgkin's Lymphoma

Hisashi Tsurumi, MD, PhD, Takashi Ibuka, MD, Takeshi Hara, MD, PhD, Hiroshi Araki, MD, Soranobu Ninomiya, MD, Naoe Goto, MD, PhD, Humito Onogi, MD, PhD, Nobuhiro Kanemura, MD, PhD, Senji Kasahara, MD, PhD, Tomohiro Kato, MD, PhD, Tsuyoshi Takami, MD, PhD, Hisataka Moriwaki, MD, PhD

Blood (2010) 116 (21): 5075.

https://doi.org/10.1182/blood.V116.21.5075.5075

Published: 2010

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

James A. Russell, FRCP, M. Ahsan Chaudhry, MD, Michelle Geddes, MD, Nizar J. Bahlis, MD, Mary Lynn Savoie, MD, Loree M. Larratt, MD, Diana M. Quinlan, BN, A. Robert Turner, MD, Alexander Balogh, MD, Jan Storek, MD, Christopher Brown, MD, Douglas A. Stewart, MD

Blood (2006) 108 (11): 3140.

https://doi.org/10.1182/blood.V108.11.3140.3140

Published: 2006

Journal Articles

Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.

Jennifer R. Brown, MD, Wendy Stock, MD, Harvey I. Katzen, MD, Agustin J. Suarez, MD, Shailendra Lakhanpal, Jose F. Leis, MD, Christopher Flowers, MD, on Behalf of ECO-1 Study Investigators

Blood (2006) 108 (11): 4989.

https://doi.org/10.1182/blood.V108.11.4989.4989

Published: 2006

NARROW

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

The IMWG Frailty Score and Age Can be More Effective Than Clinical Judgement in the Selection of Elderly Patients with Newly Diagnosed Multiple Myeloma Who Can Benefit from an Intensive Treatment Approach with High Dose Melphalan and Autologous Stem Cell Transplantation

Bortezomib-Based Induction Regimen Followed By Autologous Stem Cell Transplantation (ASCT) after Conditioning with MEL200 Is Highly Effective and Well Tolerated in Elderly Multiple Myeloma (MM) Patients up to the Age of 75 Years

Safety and Efficacy of Crizotinib in ALK-Positive Lymphomas: A Phase 1b Open-Label Study

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Safety and Tolerability of Obinutuzumab (GA101) with Shorter Duration of Infusion in Japanese Patients with Previously Untreated CD20-Positive B-Cell Non-Hodgkin's Lymphoma (NHL)-Comparison with GAO4915g (GATHER) and BO21005 (GOYA) Studies

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Severe Auto-Immune Disease Adult Patients: Analysis of Outcomes from the French Society for Bone Marrow Transplantation and Cellular Therapy (SFGMT-TC) in Light of the European Society for Blood and Marrow Transplantation (EBMT) Activity

Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Clinical Significance of Small Intestinal Involvement Detected by Double-Balloon Enteroscopy In Patients with Non-Hodgkin's Lymphoma

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Hematopoietic Stem Cell Transplantation (SCT) for Hematologic Malignancy from 10/10 Matched Unrelated Donors (MUD) with a Myeloablative Once Daily IV Fludarabine (Flu)/Busulfan Based Regimen (FLUBUP) with Thymoglobulin: Outcomes According to Stem Cell Source.

Early Estimates of Safety for Alemtuzumab Combined with Fludarabine for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia: Phase II Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only